Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9322748 | 1.00 | TACR1 (0.78) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9322752 | 1.00 | TACR1 (0.78) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9322881 | 0.91 | TACR1 (0.77) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9322890 | 0.91 | TACR1 (0.77) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL6135372 | 0.89 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL6135549 | 0.89 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL28229229 | 0.89 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9321845 | 0.89 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL28861521 | 0.89 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL4188315 | 0.89 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0409931-B1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER (US) | 1994-02-16 | — | — | EP | disclosed |
| US-5162339-A | Substance P Antagonists, Gastrointestinal and Central Nervous System Disorders, Antiinflammatory Agents, Analgesics | PFIZER INC. (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0409931-A1 | QUINUCLIDINE THERAPEUTIC AGENTS. | PFIZER (US) | 1991-01-30 | — | — | EP | disclosed |
| WO-1990005729-A1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | disclosed |
| WO-1990005525-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | disclosed |